Active Not Recruiting
PHASE3
INTERVENTIONAL
NCT06260722
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.
Interventions
Name:
Retatrutide
Type:
DRUG
Description:
Administered SC.
Name:
Semaglutide
Type:
DRUG
Description:
Administered SC.
Primary Outcomes
Measure:
Change from Baseline in Hemoglobin A1c (HbA1c) (%)
TimeFrame:
Baseline, Week 80
Description:
Trial Information
NCT ID
NCT06260722
Status
Active Not Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025